L'intérêt à découvert pour IGM Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de IGM Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

IGM Biosciences (NASDAQ:IGMS) Stock, Rapport sur les intérêts à découvert

IGM BIOSCIENCES INC

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Inc

News

Offerings

CTRI

Centuri Holdings Files For Mixed Shelf Of Up To $500M

ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital under the following terms:
An additional $25.0 million at the option of the Company any time prior to December 31, 2026; and
An additional $50.0 million at the option of the Company and Oberland Capital any time prior to December 31, 2026.
In addition to the note financing, the Company entered into a stock purchase agreement with Oberland Capital whereby Oberland Capital purchased 275,808 shares of the Company's common stock at a price of $12.69 per share in a registered direct offering, representing an additional $3,500,003.52 of gross proceeds to the Company. The price per share was equal to the trailing 30-trading days volume-weighted average price for the period ending on the day prior to the date of the stock purchase agreement. Oberland Capital also has the right to participate in a future offering of the Company's common stock in an amount of $1.5 million on or before December 31, 2026.

CLPT

ClearPoint Neuro Secures Up To $105M In Note Financing From Oberland Capital With $30M Funded At Closing, Gains Additional $3.5M Through Direct Stock Sale At $12.69/Share, And Retains Option For $75M More Plus Future $1.5M Equity Participation Through 2026

Barclays analyst Julian Mitchell maintains Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) with a Overweight and raises the price target from $155 to $160.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Regal Rexnord, Raises Price Target to $160

Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $77.07 million which beat the analyst consensus estimate of $76.28 million by 1.04 percent. This is a 1.28 percent decrease over sales of $78.08 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Village Farms Intl Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $77.07M Beat $76.28M Estimate

<a href="https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true</a>

General

'AMC to Slash Movie Ticket Prices by 50% on Wednesdays'- Bloomberg

Barclays analyst Julian Mitchell maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Equal-Weight and raises the price target from $22 to $24.

Barclays Maintains Equal-Weight on Kennametal, Raises Price Target to $24

Guidance

BSLK

Bolt Projects Holdings Sees FY2026 Revenue To Be At Least $9M

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) affirms FY2025 sales outlook from $450.00 million-$475.00 million to $450.00 million-$475.00 million vs $462.97 million estimate.

MVST

Microvast Holdings Affirms FY2025 Sales Guidance of $450.00M-$475.00M vs $462.97M Est

Bolt Projects Holdings Sees FY2025 Revenue Of Atleast $4.5M

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 15 years by 12.98% on an annualized basis producing an average annual return of 24.58%. Currently, Copart has a market capitalization of $60.14 billion. 
Buying $100 In CPRT: If an investor had bought $100 of CPRT stock 15 years ago, it would be worth $2,674.99 today based on a price of $62.25 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747084514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CPRT

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Village Farms International Announces Transformative Transaction to Privatize Its Fresh Produce Business; Village Farms' Fresh Segment To Become Cornerstone Of Newco's Commercial Operations And Growth Strategy; Expects To Receive $40M In Cash Proceeds; 37.9% Equity Ownership Interest In Newco; Retains Ownership Of All Canadian Cultivation Assets

Bolt Projects Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) reported quarterly losses of $(3.00) per share. This is a 89.37 percent increase over losses of $(28.22) per share from the same period last year. The company reported $171.00 thousand in sales this quarter. This is a 800.00 percent increase over sales of $19.00 thousand the same period last year.

Bolt Projects Holdings Q1 EPS $(3.00) Up From $(28.22) YoY, Sales $171.00K Up From $19.00K YoY

Central Puerto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEPU#NYSE">CEPU</a>) reported quarterly earnings of $0.50 per share. This is a 150 percent increase over earnings of $0.20 per share from the same period last year. The company reported $196.00 million in sales this quarter. This is a 130.67M percent increase over sales of $150.00 the same period last year.

CEPU

Central Puerto Q1 EPS $0.50 Up From $0.20 YoY, Sales $196.00M Up From $150.00 YoY

Barclays analyst Adrienne Yih maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Overweight and lowers the price target from $38 to $23.

VSCO

Barclays Maintains Overweight on Victoria's Secret, Lowers Price Target to $23

Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.57 by 24.56 percent. This is a 28.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $35.70 million which missed the analyst consensus estimate of $43.13 million by 17.23 percent. This is a 17.44 percent decrease over sales of $43.24 million the same period last year.

LEGH

Legacy Housing Q1 EPS $0.43 Misses $0.57 Estimate, Sales $35.70M Miss $43.13M Estimate

LSEAW

Trading Halt: Halted at 5:12:38 p.m. ET - Trading Halt: Halt News Pending

LSEA

EVI Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EVI#AMEX">EVI</a>) reported quarterly earnings of $0.07 per share. This is a 16.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported $93.54 million in sales this quarter. This is a 11.38 percent increase over sales of $83.98 million the same period last year.

EVI Industries Q3 EPS $0.07 Up From $0.06 YoY, Sales $93.54M Up From $83.98M YoY

Barclays analyst Adrienne Yih maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Overweight and lowers the price target from $34 to $19.

Barclays Maintains Overweight on VF, Lowers Price Target to $19

Tecogen (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#AMEX">TGEN</a>) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported $7.28 million in sales this quarter. This is a 17.65 percent increase over sales of $6.19 million the same period last year.

Comments

IGM Biosciences

Intérêt court

IGM Biosciences (NASDAQ:IGMS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL